FDA Approves New Biweekly Dosing of Johnson & Johnson’s Tecvayli for Relapsed/Refractory Multiple Myeloma

Tecvayli is an off-the-shelf bispecific antibody previously granted accelerated approval by the FDA for adults with relapsed/refractory multiple myeloma.

Source link
#FDA #Approves #Biweekly #Dosing #Johnson #amp #Johnsons #Tecvayli #RelapsedRefractory #Multiple #Myeloma